STOCK TITAN

Alphatec Holdings Inc - ATEC STOCK NEWS

Welcome to our dedicated news page for Alphatec Holdings (Ticker: ATEC), a resource for investors and traders seeking the latest updates and insights on Alphatec Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alphatec Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alphatec Holdings's position in the market.

Rhea-AI Summary
Alphatec Holdings, Inc. (Nasdaq: ATEC) will report first quarter 2024 financial results on May 7, 2024, after the market close. The Company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. Inducement awards were granted to 14 new employees with 16,289 restricted stock units. RSUs will vest annually over four years or fully upon a change of control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
conferences earnings
-
Rhea-AI Summary
Spineology Inc. appoints Emory Rooney as Executive Vice President, Sales, to drive U.S. market growth with his 20 years of spine sales experience in medical devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
management
-
Rhea-AI Summary
Alphatec Holdings, Inc. (Nasdaq: ATEC) reports a 37% growth in total revenue for full year 2023, reaching $482 million, with an improved adjusted EBITDA margin. Expectations for full year 2024 revenue approximate $595 million, anticipating a 23% growth compared to 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.87%
Tags
News
Rhea-AI Summary
Alphatec Holdings, Inc. (Nasdaq: ATEC) announced its participation in upcoming investor conferences and the presentation of an updated long-range financial plan. The company also disclosed the approval of inducement awards for 58 new employees in the form of restricted stock units (RSUs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
Rhea-AI Summary
Alphatec Holdings, a provider of innovative solutions for spine surgery, reported a 37% increase in total revenue to over $480 million for full-year 2023. The company expects total revenue of $595 million for full-year 2024. Surgical revenue for the fourth quarter ended December 31, 2023, was in the range of $121.8M to $122.8M, with total revenue in the range of $136.8M to $138.4M. The company's continued strong momentum in the lateral franchise fueled portfolio-wide adoption and surgical revenue growth of 39% to 40% in 2023. Surgical volume growth accelerated to 31% compared to 25% in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.1%
Tags
none
-
Rhea-AI Summary
Alphatec Holdings, Inc. (Nasdaq: ATEC) will present at the J.P. Morgan Healthcare Conference on January 10, 2024, to showcase innovative solutions for spine surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
conferences
Rhea-AI Summary
Spineology Inc. (NASDAQ: SPIN) appoints Brian Snider as new CEO, effective November 13, 2023, following John Booth's retirement. Snider brings nearly 20 years of experience in the medical device industry, previously serving as Executive VP of Marketing for Alphatec Spine. The Board of Directors expressed confidence in Snider's ability to lead the company's growth and surgical advancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
-
Rhea-AI Summary
Alphatec Holdings, Inc. (Nasdaq: ATEC) reported strong financial results for the quarter ended September 30, 2023. Total revenue grew 32% to $118 million, with surgical revenue growing 32% to $104 million and EOS revenue growing 30% to $14 million. The company delivered positive adjusted EBITDA of over $2 million and ended the quarter with a cash balance of $123 million. Recent highlights include the launch of Calibrate LTXTM, a lateral expandable implant system, a 24% increase in surgical volume, and a 6% increase in average revenue per procedure. Alphatec also secured $150 million in capital to accelerate investment in revenue-generating assets and enhanced its Board of Directors with deep spine expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
-
Rhea-AI Summary
Alphatec Holdings, Inc. (Nasdaq: ATEC) will participate in several upcoming investor events, including the Stifel Healthcare Conference, the Jefferies London Healthcare Conference, the Piper Sandler Healthcare Conference, the Truist Securities MedTech West Coast Bus Tour, and the Stifel Medtech Madness West Coast Bus Tour. Webcasts and archived recordings of the conference presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
conferences
Rhea-AI Summary
Alphatec Holdings, Inc. has successfully closed a $150 million secondary offering, positioning the company to invest in revenue-generating assets and capitalize on industry disruptions. The company expects third quarter 2023 total revenue growth of 31 to 32% and full-year 2023 total revenue of approximately $472 million. Alphatec Holdings will announce its third quarter 2023 financial and operating results on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
Alphatec Holdings Inc

Nasdaq:ATEC

ATEC Rankings

ATEC Stock Data

1.82B
97.84M
34.75%
67.15%
8.96%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Carlsbad

About ATEC

as a medical technology company, we improve lives by providing innovative spine surgery solutions through our relentless pursuit of superior outcomes. we are dedicated to the design, development, launch and the delivery of spinal fusion products. we seek to accomplish this by working with spine surgeons to design and develop products and systems that address the entire spinal fusion procedure in the most effective and efficient way possible. our product designs and platforms provide innovation through a focus on simplifying procedures for the surgeon with the ultimate objective of superior outcomes. alphatec spine is seeking growth through innovation and continually developing technologies that will have a greater positive impact on patient care and outcomes. please visit our website for more information: www.alphatecspine.com